Long-term survivors with immunotherapy in advanced NSCLC: is ‘cure’ within reach?

Sara Monteverdi, Emanuele Vita, Giulia Sartori, Miriam Grazia Ferrara, Ettore D’Argento, Giampaolo Tortora, Michele Milella, Emilio Bria, Sara Pilotto

Abstract

Lung cancer represents the main cause of cancer-related death globally. In recent years, the introduction of immune checkpoint inhibitors (ICIs) have changed prognosis in a relevant proportion of non-small cell lung cancer (NSCLC) patients, especially in immunogenic tumors, such as the smoke-related ones.